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Due to the high capital costs for a new roller bottle facility, a new suspension bioreactor perfusion platform was 
pursued as a potential option to improve the supply network for an existing commercial roller bottle cell culture 
process.  The first step in developing the bioreactor process was the adaptation of the current commercial 
working cell bank to serum-free, suspension conditions.  Subcloning of this serum-free, suspension adapted 
pool was performed to reduce the pool to the top 50 clones based on titer and activity.  In deep well plates and 
shake flask cultures, the top 50 clones were further screened to yield the top 10 clones based on yield, activity, 
and important product quality attributes including sialylation and Mannose-6-Phosphate (M6P) content, which 
were determined by high throughput analytical methods specifically designed for this molecule.  In parallel with 
these activities, an ambr® 15 perfusion scale down model was developed to evaluate multiple process levers 
(e.g. medium osmolarity, target viable cell concentration, cell specific perfusion rate, etc.) for the serum-free, 
suspension adapted pool using definitive screening designs.  After ambr® 15 scale down model development, 
the Top 10 clones identified in subcloning were evaluated in the top conditions identified from the process lever 
optimization study.  Several of the best combinations of clones / bioreactor conditions were then repeated in 10L 
bench scale bioreactors to ensure reproducible cell culture performance.  Furthermore, the 10L cultures were 
harvested and purified to mock drug substance to confirm significant product quality attributes were consistent 
between the ambr® 15 scale down model and bench scale bioreactors and within desired commercial 
specification ranges.  These results suggest that the ambr® 15 perfusion scale down model can be deployed for 
clone selection, process optimization, and process characterization activities for the current suspension, 
perfusion bioreactor process, as well as development of future perfusion processes, to ensure successful launch 
at large scale. 
 
 
